Cepheid is a leading molecular diagnostics and testing company headquartered in Sunnyvale, California, United States. It was founded in 1996 by Thomas Gutshall, Carl Wittwer, and Richard Mathies, with the aim to develop and market innovative solutions for accurate and rapid molecular testing. Cepheid is known for its expertise in the field of molecular diagnostics and its commitment to enabling the diagnosis and monitoring of diseases at the point of care.

The company's main product line is its GeneXpert system, which provides robust and accurate molecular diagnostics on a variety of diseases including infectious diseases, healthcare-associated infections, sexually transmitted infections, and genetic diseases. The GeneXpert system combines sample preparation, amplification, and detection of nucleic acids in a fully integrated and automated cartridge. With a global reach, Cepheid operates in more than 120 countries worldwide.

The company has established several subsidiaries, joint ventures, and partnerships to expand its presence and offer localized support. Notable partnerships include collaborations with FIND (Foundation for Innovative New Diagnostics), USAID, and the World Health Organization. These partnerships have helped Cepheid reach underserved areas and develop tests for diseases prevalent in resource-limited settings.

Cepheid holds a strong market position in the molecular diagnostics industry, with a focus on point-of-care testing. As one of the pioneers in this field, the company has been able to establish itself as a trusted brand globally. It faces competition from other molecular diagnostic companies like Roche Diagnostics, Qiagen, and Abbott Laboratories.

Over the years, Cepheid has achieved significant milestones and made important contributions to the field of molecular diagnostics. In 2015, the company received FDA approval for the first Ebola test using the GeneXpert system. This played a crucial role in controlling the Ebola outbreak in West Africa.

Cepheid's strategic acquisition by Danaher Corporation in 2016 further strengthened its position in the market and provided additional resources for growth and innovation. As of the latest information available, Cepheid continues to innovate and expand its test menu for a wide range of diseases. It remains at the forefront of molecular diagnostics and point-of-care testing, providing healthcare professionals with reliable and efficient tools for accurate diagnosis and monitoring of diseases